Zai Lab Limited (NASDAQ:ZLAB) Shares Purchased by Wellington Management Group LLP

Wellington Management Group LLP boosted its stake in shares of Zai Lab Limited (NASDAQ:ZLAB - Free Report) by 18.4% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 8,436,606 shares of the company's stock after purchasing an additional 1,312,115 shares during the period. Wellington Management Group LLP owned approximately 8.47% of Zai Lab worth $203,660,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of ZLAB. Janus Henderson Group PLC grew its position in Zai Lab by 34.2% during the 3rd quarter. Janus Henderson Group PLC now owns 8,760,074 shares of the company's stock worth $211,488,000 after purchasing an additional 2,232,507 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its position in Zai Lab by 26.2% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 604,153 shares of the company's stock worth $14,584,000 after purchasing an additional 125,532 shares during the last quarter. Bamco Inc. NY grew its position in Zai Lab by 6.4% during the 3rd quarter. Bamco Inc. NY now owns 1,906,520 shares of the company's stock worth $46,023,000 after purchasing an additional 113,869 shares during the last quarter. Algert Global LLC purchased a new stake in Zai Lab during the 3rd quarter worth approximately $1,666,000. Finally, Hennion & Walsh Asset Management Inc. grew its position in Zai Lab by 96.5% during the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 124,096 shares of the company's stock worth $2,151,000 after purchasing an additional 60,927 shares during the last quarter. Hedge funds and other institutional investors own 41.65% of the company's stock.

Zai Lab Trading Up 3.4 %

Shares of ZLAB stock traded up $0.94 during trading hours on Monday, hitting $28.91. The company's stock had a trading volume of 780,854 shares, compared to its average volume of 717,932. The company has a 50 day moving average of $27.99 and a 200 day moving average of $22.02. Zai Lab Limited has a 12-month low of $13.48 and a 12-month high of $36.60. The stock has a market cap of $3.14 billion, a PE ratio of -10.10 and a beta of 0.99.

Analyst Ratings Changes

Several analysts have recently commented on the stock. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Zai Lab in a report on Friday, October 25th. JPMorgan Chase & Co. upped their price objective on shares of Zai Lab from $38.00 to $44.00 and gave the company an "overweight" rating in a report on Monday, October 21st.

About Zai Lab

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.